Given that hepatic steatosis, glucose intolerance and insulin resistance are common complications during obesity and that our data indicate that PSOn treatment effectively improved glucose and insulin levels in HFD-fed mice, we decided to evaluate if the hepatic steatosis could also be improved. This evidence concerns the gene INS and fatty liver disease.